{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:18:48Z","timestamp":1781273928553,"version":"3.54.1"},"reference-count":36,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder, due to the loss of function of the survival motor neuron (<jats:italic>SMN1<\/jats:italic>) gene. The first treatment for the condition, recently approved, is based on the reduction of exon 7 skipping in mRNAs produced by a highly homologous gene (<jats:italic>SMN2<\/jats:italic>). The primary objective of the present study was to evaluate the applicability of the dosage of SMN gene produts in blood, as biomarker for SMA, and the safety of oral salbutamol, a beta2-adrenergic agonist modulating <jats:italic>SMN2<\/jats:italic> levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We have performed a 1-year multicentre, double-blind, placebo-controlled study with salbutamol in 45 adult patients with SMA. Patients assumed 4\u2009mg of salbutamol or placebo\/three times a day. Molecular tests were <jats:italic>SMN2<\/jats:italic> copy number, SMN transcript and protein levels. We have also explored the clinical effect, by the outcome measures available at the time of study design.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-six patients completed the study. Salbutamol was safe and well tolerated. We observed a significant and progressive increase in <jats:italic>SMN2<\/jats:italic> full-length levels in peripheral blood of the salbutamol-treated patients (p&lt;0.00001). The exploratory analysis of motor function showed an improvement in most patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data demonstrate safety and molecular efficacy of salbutamol. We provide the first longitudinal evaluation of SMN levels (both transcripts and protein) in placebo and in response to a compound modulating the gene expression: <jats:italic>SMN<\/jats:italic> transcript dosage in peripheral blood is reliable and may be used as pharmacodynamic marker in clinical trials with systemic compounds modifying <jats:italic>SMN2<\/jats:italic>levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>EudraCT no. 2007-001088-32.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jmedgenet-2018-105482","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T22:15:20Z","timestamp":1546035320000},"page":"293-300","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol"],"prefix":"10.1136","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-6158","authenticated-orcid":false,"given":"Francesco Danilo","family":"Tiziano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lomastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Abiusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Barbara","family":"Pasanisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Sorar\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Mongini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Vercelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gessica","family":"Vasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Petillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Passamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Politano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Campanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,12,28]]},"reference":[{"key":"2020050722260649000_56.5.293.1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90460-3"},{"key":"2020050722260649000_56.5.293.2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9"},{"key":"2020050722260649000_56.5.293.3","doi-asserted-by":"publisher","DOI":"10.1086\/338627"},{"key":"2020050722260649000_56.5.293.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2007.02.006"},{"key":"2020050722260649000_56.5.293.5","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1884910"},{"key":"2020050722260649000_56.5.293.6"},{"key":"2020050722260649000_56.5.293.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"2020050722260649000_56.5.293.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"2020050722260649000_56.5.293.9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol"},{"key":"2020050722260649000_56.5.293.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.4.609"},{"key":"2020050722260649000_56.5.293.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2008.05.004"},{"key":"2020050722260649000_56.5.293.12","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2007.051177"},{"key":"2020050722260649000_56.5.293.13","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2010.080366"},{"key":"2020050722260649000_56.5.293.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010819"},{"key":"2020050722260649000_56.5.293.15","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2009.116"},{"key":"2020050722260649000_56.5.293.16","doi-asserted-by":"crossref","unstructured":"Kobayashi DT , Olson RJ , Sly L , Swanson CJ , Chung B , Naryshkin N , Narasimhan J , Bhattacharyya A , Mullenix M , Chen KS . Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses. PLoS One 2011;6:e24269.doi:10.1371\/journal.pone.0024269","DOI":"10.1371\/journal.pone.0024269"},{"key":"2020050722260649000_56.5.293.17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ejhg.2012.233","article-title":"Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study","volume":"21","author":"Tiziano","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"2020050722260649000_56.5.293.18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2500\/ajr.2007.21.3015","article-title":"Argl6gly polymorphism of the beta2-adrenoceptor gene (ADRBeta2) as a susceptibility factor for nasal polyposis","volume":"21","author":"Bussu","year":"2007","journal-title":"Am J Rhinol"},{"key":"2020050722260649000_56.5.293.19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ptj\/72.2.115","article-title":"Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne\u2019s muscular dystrophy","volume":"72","author":"Florence","year":"1992","journal-title":"Phys Ther"},{"key":"2020050722260649000_56.5.293.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2009.06.368"},{"key":"2020050722260649000_56.5.293.21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d3e308"},{"key":"2020050722260649000_56.5.293.22","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e318183e0fa"},{"key":"2020050722260649000_56.5.293.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb02939.x"},{"key":"2020050722260649000_56.5.293.24","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23937"},{"key":"2020050722260649000_56.5.293.25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1081-1206(10)63356-X","article-title":"Elevation of creatine kinase from skeletal muscle associated with inhaled albuterol","volume":"77","author":"Craig","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2020050722260649000_56.5.293.26","first-page":"371","article-title":"Creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) activity in serum before and after intravenous salbutamol administration of patients with bronchial asthma","volume":"30","author":"Chazan","year":"1992","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"2020050722260649000_56.5.293.27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1212\/WNL.0b013e318295d766","article-title":"Pilot trial of clenbuterol in spinal and bulbar muscular atrophy","volume":"80","author":"Querin","year":"2013","journal-title":"Neurology"},{"key":"2020050722260649000_56.5.293.28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318271f7e4"},{"key":"2020050722260649000_56.5.293.29","doi-asserted-by":"crossref","unstructured":"Swoboda KJ , Scott CB , Reyna SP , Prior TW , LaSalle B , Sorenson SL , Wood J , Acsadi G , Crawford TO , Kissel JT , Krosschell KJ , D\u2019Anjou G , Bromberg MB , Schroth MK , Chan GM , Elsheikh B , Simard LR . Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009;4:e5268.doi:10.1371\/journal.pone.0005268","DOI":"10.1371\/journal.pone.0005268"},{"key":"2020050722260649000_56.5.293.30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"2020050722260649000_56.5.293.31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2020050722260649000_56.5.293.32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001952"},{"key":"2020050722260649000_56.5.293.33","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1111\/sms.12312","article-title":"Impact of salbutamol on muscle metabolism assessed by \u00b3\u00b9P NMR spectroscopy","volume":"25","author":"Decorte","year":"2015","journal-title":"Scand J Med Sci Sports"},{"key":"2020050722260649000_56.5.293.34","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00741"},{"key":"2020050722260649000_56.5.293.35","doi-asserted-by":"crossref","unstructured":"Kobayashi DT , Shi J , Stephen L , Ballard KL , Dewey R , Mapes J , Chung B , McCarthy K , Swoboda KJ , Crawford TO , Li R , Plasterer T , Joyce C , Chung WK , Kaufmann P , Darras BT , Finkel RS , Sproule DM , Martens WB , McDermott MP , De Vivo DC , Walker MG , Chen KS . Biomarkers for Spinal Muscular Atrophy Study Group Pediatric Neuromuscular Clinical Research Network. SMA-MAP: a plasma protein panel for spinal muscular atrophy. PLoS One 2013;8:e60113.doi:10.1371\/journal.pone.0060113","DOI":"10.1371\/journal.pone.0060113"},{"key":"2020050722260649000_56.5.293.36","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1038\/mtna.2016.47","article-title":"Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy","volume":"5","author":"Catapano","year":"2016","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2018-105482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T15:14:01Z","timestamp":1601046841000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2018-105482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,28]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,4,25]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/jmedgenet-2018-105482"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2018-105482","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,28]]}}}